Xin Lang Cai Jing·2025-12-26 12:21Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued a notice of administrative penalty against Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for suspected false reporting of financial data, revealing that the company inflated revenue and profits for three consecutive years, violating securities laws and regulations [1][5][6]. Group 1: Penalties and Actions - The CSRC plans to impose a fine of 10 million yuan on the company and a total of 31 million yuan in fines on 14 responsible individuals [1][6]. - The former general manager, Luo Ming, will face a lifetime ban from the securities market [1][6]. - The Shenzhen Stock Exchange will initiate delisting procedures due to the company's suspected major violations [1][6]. Group 2: Investigation and Compliance - The CSRC is conducting a simultaneous investigation into the practices of intermediary institutions, with potential penalties for any identified violations [1][6]. - The CSRC will transfer any criminal evidence to the public security authorities in accordance with legal standards [1][6]. Group 3: Stock Performance - As of December 26, the stock price of *ST Changyao was 1.47 yuan, with a market capitalization of 515 million yuan [4][9].